Meta-analysis of the efficacy and safety of tripterygium glycosides versus RAAS blockers in the treatment of diabetic kidney disease

Objective To evaluate the efficiency and safety of tripterygium glycosides (TG) in the treatment of diabetic kidney disease compared with RAAS blockers. Methods Meta-analysis of retrieved results and data was performed through CNKI, CBM, VIP, Wanfang data, Embase, Pubmed, and Cochrane Library databases. Results A total of 14 articles were retrieved, The results of efficiency showed that the TG group was better than the RAAS blocker group, with statistically significant differenceOR=3.91,95% CI(1.91,8.01),P=0.0002. The results of UP showed that decrease magnitude in the test group was lower than that in the control group, with statistically significant differenceMD=-0.53,95% CI(-0.77,-0.29),P<0.0001. The results of BUN showed that the BUN in the test group was lower than that in the control group, with statistically significant differenceMD=-2.20,95% CI (-2.79,-1.61),P<0.00001. The results of Scr showed that the result between test group and control group were equally effective, with no statistically significant differenceMD=-5.47,95% CI (-11.04,-0.11),P=0.05; with respect to adverse reactions, the test group was comparable to the control group, with no statistically significant differenceMD=1.01,95% CI (0.56,1.82),P=0.46. Conclusions The overall efficiency of TG in the treatment of diabetic kidney disease is significant. It has lower UP, BUN and Scr levels compared with RAAS blockers, while its adverse reaction incidence is comparable to that of RAAS blockers.